Aug 1 (Reuters) - German Chemicals Group Evonik Industries Evkn.de on Thursday Said It Expected Its Core Profit for the Third Quarter to Be "on Par" With That of the Second Quarter.
8月1日(路透社)-德國化學品集團Evonik Industries表示,預計第三季度核心利潤將與第二季度“持平”。 Evkn.de 這家特種化學制品製造商表示,其二季度調整後的息稅折舊攤銷前利潤(EBITDA)爲5,7800萬歐元(62,600萬美元),與7月份公佈的初步數字一致。
The Speciality Chemicals Maker Said Its Second-Quarter Adjusted Earnings Before Interest, Tax, Depreciation and Amortisation (Ebitda) Was 578 Million Euros ($626 Million), in Line With the Preliminary Figure Published in July.
這家專業化學制品製造商表示,其二季度調整後的息稅折舊攤銷前利潤(EBITDA)爲5,7800萬歐元(62,600萬美元),與7月份公佈的初步數字一致。 初步數字 ,該數字已於7月公佈。
Evonik, Whose Chemicals Are Used in Products From Autos and Animal Feed to Pfizer and BioNTech's Covid Vaccine, Confirmed Its Annual Outlook for an Adjusted Ebitda of Between 1.9 Billion and 2.2 Billion Euros, Which It Raised Last Month.
Evonik的化學品被用於從汽車和動物飼料到輝瑞和BioNTech的新冠疫苗等產品中。該公司確認其年度展望,即調整後的EBITDA在19億至22億歐元之間,這一數字在上個月發佈。 募資額 上個月發佈
The Outlook for Its Other Key Financial Figures Also Remains Unchanged, Evonik Added.
Evonik補充道,其其他關鍵財務指標的展望也保持不變。
"We Are Headed in the Right Direction, and the Improvements in Our Key Financial Figures Compared to the Previous Year Are Really Encouraging," Chief Financial Officer Maike Schuh Said in a Statement.
“我們正在朝着正確的方向前進,與上一年相比,我們的主要財務指標的改善真正鼓舞人心,”首席財務官Maike Schuh在一份聲明中說。
"However, the Current Recovery Compares to a Very Weak 2023, and We Are Still a Long Way From Reaching Our Goals," Schuh Added.
Schuh補充道:“然而,與2023年的低迷情況相比,目前的復甦還有很長的路要走,我們離達成我們的目標還有很長的路要走。”
The Company Said It Expected the Sale of Its Superabsorbents Business to Be Completed During the Third Quarter.
該公司表示預計其超吸水性業務的出售將在第三季度完成。 出售 其超吸收業務的出售將在第三季度完成。
($1 = 0.9232 Euros)
($1 = 0.9232歐元)
(Reporting by Anastasiia Kozlova and Amir Orusov in Gdansk; Editing by Milla Nissi)
(文 by Anastasiia Kozlova 和 Amir Orusov,Gdansk報道;Milla Nissi編輯)